Investigational Drug Details
| Drug ID: | D409 |
| Drug Name: | Nicotinamide |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB02701 |
| DrugBank Description: | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. |
| PubChem ID: | 936 |
| CasNo: | 98-92-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NC(=O)C1=CC=CN=C1 |
| Structure: |
|
| InChiKey: | DFPAKSUCGFBDDF-UHFFFAOYSA-N |
| Molecular Weight: | 122.1246 |
| DrugBank Targets: | ADP-ribosyl cyclase 2; Exotoxin A; NAD-dependent protein deacylase sirtuin-5, mitochondrial; L-lactate dehydrogenase A chain; Poly [ADP-ribose] polymerase 1 |
| DrugBank MoA: | |
| DrugBank Pharmacology: | |
| DrugBank Indication: | |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0502 | NCT01365481 | PHASE3 | COMPLETED | YES | 2011-08 | 2016-07-13 | Details |
| L0636 | NCT05757557 | PHASE1|PHASE2 | COMPLETED | NO | 2023-02-25 | 2025-04-10 | Details |
| L0889 | NCT03703154 | COMPLETED | NO | 2018-10-25 | 2021-04-27 | Details | |
| L1002 | NCT00490737 | PHASE1 | COMPLETED | NO | 2007-08-12 | 2018-01-09 | Details |
| L1653 | NCT01151592 | PHASE4 | WITHDRAWN | NO | 2018-01-24 | Details | |
| L2417 | NCT00516048 | PHASE3 | COMPLETED | YES | 2007-08 | 2015-04-07 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|